Evidence map›Paper›PMID 39891280›Full record

ArticleActa neuropathologica communications2025

Dynamics of retinal changes in early-stage Parkinson's disease.

Ane Murueta-Goyena, Sara Teijeira-Portas, Elisa Blanco Martín, Raquel Vázquez-Picón, Blanca Ruiz Bajo, Jone Bocos, Jorge Sánchez-Molina, Patricia Alves Dias, Ioana Croitoru, Iñaki Rodríguez Agirretxe and 9 more

Abstract readMulticenter Study
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Retinal Neurovascular Signatures in Parkinson's Disease.Investigative ophthalmology & visual science · 2025
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ane Murueta-GoyenaDepartment of Neurosciences, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Leioa, Spain. ane.muruetagoyena@ehu.eus.ORCID 0000-0002-9808-6943
Sara Teijeira-PortasNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.ORCID 0000-0002-2208-5864
Elisa Blanco MartínHospital de Urduliz Alfredo Espinosa - OSI Uribe, Urduliz, Bizkaia, Spain.ORCID 0000-0002-2765-4018
Raquel Vázquez-PicónServicio Neurología, Hospital Universitario Galdakao-Usansolo, Galdakao, Bizkaia, Spain.
Blanca Ruiz BajoServicio Neurología, Hospital Universitario Araba, Vitoria-Gasteiz, Araba, Spain.
Jone BocosServicio Neurología, Hospital Universitario Araba, Vitoria-Gasteiz, Araba, Spain.
Jorge Sánchez-MolinaServicio Oftalmología, Hospital Universitario Donostia, Donostia, Gipuzkoa, Spain.ORCID 0000-0002-0453-7919
Patricia Alves DiasBiogipuzkoa Health Research Institute, Donostia, Gipuzkoa, Spain.
Ioana CroitoruBiogipuzkoa Health Research Institute, Donostia, Gipuzkoa, Spain.
Iñaki Rodríguez AgirretxeServicio Oftalmología, Hospital Universitario Donostia, Donostia, Gipuzkoa, Spain.ORCID 0000-0001-8645-4991
Rocío Del PinoNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.ORCID 0000-0002-6612-4757
Marian AceraNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.ORCID 0000-0002-8333-0659
Beatriz TijeroNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.ORCID 0000-0001-9894-5712
Oihane Sáez-AtxukarroFacultad de Psicología, Universidad Pública de Navarra, Iruña, Navarra, Spain.ORCID 0000-0001-9657-5527
David Romero-BasconesBiomedical Engineering Department, Faculty of Engineering (MU-ENG), Mondragon Unibertsitatea, Arrasate, Spain.ORCID 0000-0002-2201-859X
Juan Carlos Gómez-EstebanDepartment of Neurosciences, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Leioa, Spain.ORCID 0000-0002-4697-3890
Javier Aritz UrcolaServicio Oftalmología, Hospital Universitario Araba, Vitoria-Gasteiz, Araba, Spain.ORCID 0000-0001-7084-2877
Javier Ruiz MartínezBiogipuzkoa Health Research Institute, Donostia, Gipuzkoa, Spain.ORCID 0000-0001-7326-6270
Iñigo GabilondoNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.ORCID 0000-0001-6045-2840

Funding

Osasun Saila, Eusko Jaurlaritzako 2019111100
6 · The paper itself

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder primarily characterized by motor symptoms, with emerging evidence suggesting retinal pathology, particularly in the ganglion cell-inner plexiform layer (GCIPL), detectable via optical coherence tomography (OCT). This study aimed to characterize early retinal dynamics in PD using OCT. We conducted a prospective one-year longitudinal multicenter study involving 53 early-stage PD patients with a disease duration of 5 years or less and 52 controls. The participants underwent retinal spectral-domain OCT, primary visual function and cognitive examinations. We examined baseline retinal measures and short-term longitudinal differences between groups via linear mixed effects models. In PD patients, the baseline GCIPL thickness in central regions was increased by up to 4 μm, and the rate of thinning in the parafoveal GCIPL was - 0.61 [0.29] µm/year faster over a one-year follow-up period than in controls in the 2- to 3-mm ring (p = 0.039). In PD patients, greater central GCIPL thickness was associated with poorer contrast sensitivity and reduced performance on the Farnsworth D15 color vision test. It also predicted subsequent thinning in both the GCIPL (2- to 3-mm ring) and the inner nuclear layer (2- to 5-mm rings). However, this increased thickness was not linked to prevalent or progressive motor or cognitive manifestations. In conclusion, this study provides the first detailed topographical description of early retinal dynamics in PD patients, revealing increased central GCIPL thickness and accelerated parafoveal GCIPL thinning in PD. However, the macular region shows complex and variable dynamics among PD patients, but these changes precede detectable progression in clinical scales.

Indexed as

Parkinson DiseaseRetinaAgedDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesRetinal Ganglion CellsTomography, Optical CoherenceFoveaGanglion cell-inner plexiform layerOptical coherence tomographyParkinson’s diseaseRetina

Identifiers

PMID39891280
PMCPMC11784094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.